Peptron said Friday that the company would present its new diabetes treatment that continuously acts for one month at the American Diabetes Association (ADA) conference in June.

The company said it submitted its research results to ADA in January and recently received approval to introduce the drug at the poster session.

Based on its drug delivery technology, Peptron completed the development of clinical substances for long-term continuous GLP-1 series diabetes treatment. The company is seeking a global partnership for its clinical trials and commercialization. Through the ADA conference presentation, Peptron will make public the treatment’s differentiated effects and advantages.

Peptron said the company would unveil a diabetes treatment with effects that last a month at the American Diabetes Association (ADA) conference in June.
Peptron said the company would unveil a diabetes treatment with effects that last a month at the American Diabetes Association (ADA) conference in June.

GLP-1 is a next-generation diabetes drug that can replace insulin, as it has a good blood sugar control effect and only works when the blood sugar is high. Unlike insulin injectors, there is no risk of hypoglycemic shock and weight loss, according to Peptron.

The GLP-1 diabetes market has grown to 12 trillion won ($10.6 billion) thanks to the success of drugs that last a week. The market size is expected to reach 20 trillion won by 2027 if a month-long treatment attains a similar success. However, the development of existing technology is limited due to side effects when doses are increased. 

“We overcame existing limitations by establishing GMP production process which controls the emission concentration of drugs based on smart depot technology,” a Peptron official said. “We expect to change the paradigm of diabetes market with the completion of the one-month long-lasting diabetes treatment.”
 

Copyright © KBR Unauthorized reproduction, redistribution prohibited